查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933360

全球大环内酯类抗生素市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考察及未来预测（2026-2034）

Macrolide Antibiotics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 请询问到货日

价格

大环内酯类抗生素市场成长因子

2025年全球大环内酯类抗生素市场规模达到61.6亿美元，预计2026年将成长至63.7亿美元，到2034年将达到88.3亿美元，预测期内年复合成长率（CAGR）为4.17%。北美地区在2025年占据47.39%的市场占有率，这主要得益于该地区细菌感染的高发生率、先进的医疗基础设施以及强大的研发投入。大环内酯类抗生素是一类透过与细菌核醣体的50S亚基结合来抑制细菌蛋白质合成的药物。这些药物，包括阿奇霉素、克拉霉素和红霉素，用于治疗严重的感染，特别是在儿童中，例如呼吸道感染、皮肤感染、性传染病和弯曲桿菌感染。

市场上的主要公司，包括 Pfizer Inc.、Teva Pharmaceutical Industries Ltd.、Merck & Co., Inc.，正致力于扩大全球市场准入、推出仿製药以及投资开发创新型大环内酯类药物。

市场动态

驱动因素：全球细菌感染病例的增加是市场成长的主要驱动因素。呼吸道感染、性传染感染（STI）和皮肤感染病例的增加推动大环内酯类药物的需求。例如，根据世界卫生组织2024年7月的资料，15至49岁成年人中将新增8,240万例淋病病例。此外，零售处方量也在上升，2023年美国每千人开出约105张处方，这推动大环内酯类药物的使用。

限制因素：由于生产缺陷导致的频繁产品召回会损害消费者信任和品牌声誉，阻碍市场成长。例如，2025年2月，新加坡卫生科学局因无菌问题召回了500毫克克拉霉素粉剂；2023年12月，英国药品和保健产品监管局（MHRA）也因医疗缺陷召回了克拉霉素片剂。

机会：新兴市场日益重视本土药物研发，带来了巨大的机会。价格合理的本地化生产有助于缓解亚洲、非洲和拉丁美洲沉重的疾病负担。例如，在BIRAC的支持下，印度于2024年11月推出了用于治疗抗药性社区获得性细菌性肺炎的萘菲霉素（Miqnaf）。

挑战：大环内酯类药物的副作用（例如胃肠道不适、噁心和QT间期延长）是长期使用的障碍，尤其是红霉素。这些副作用增加了密切监测的必要性，并限制了其在易感人群中的使用。

市场趋势

持续的药物研发和创新是关键趋势。研究重点在于对抗抗生素抗药性。例如，2024年7月，伊利诺大学研发 "大环内酯类抗生素" （macrolone），这是一种双效抗生素，可同时靶向核醣体蛋白合成和DNA复製，使细菌难以产生抗药性。这些进展塑造未来的市场策略，并有助于提高全球大环内酯类药物的疗效。

市场区隔分析

依产品划分：阿奇霉素以其广谱抗菌活性、长半衰期和极少的胃肠道副作用，占据市场主导地位。克拉霉素也拥有较大的市场占有率，尤其是在幽门螺旋桿菌感染的治疗方面。红霉素则受益于仿製药的上市及其在儿科领域的应用。油霉素和其他大环内酯类抗生素预计将保持稳定成长。

依疾病区分：呼吸道感染是推动市场成长的主要因素，包括肺炎、鼻窦炎、咽炎和白喉。由于衣原体感染和淋病病例的增加，性传染感染（STI）预计将会成长。皮肤感染的年复合成长率适中，主要受痤疮和金黄色葡萄球菌感染的推动。

给药途径：口服製剂因其使用方便且易于取得而占据主导地位，而注射製剂则用于需要快速起效的住院患者。可局部使用的外用製剂正稳定成长。

年龄组：儿科患者占比最大，因为许多大环内酯类药物已获准用于儿科。成人用药量也在上升，这得益于新的成人产品上市和监管部门的批准。

分销通路：零售药局和药局占最大占有率，2022年美国共开立3,610万张大环内酯类处方。由于其便利性、隐私性和成本优势，线上药局也在不断发展。由于医院药房在医疗机构中被用作一线治疗药物，因此其市场占有率仍然相当可观。

区域展望

北美：受传染病流行、积极的研发活动和资金投入的推动，到2025年，北美市场规模达到29.2亿美元。美国凭藉仿製药的上市和在对抗抗生素抗药性方面的投资，在该地区处于领先地位。

欧洲：在广谱抗生素需求不断成长的推动下，欧洲占据第二大市场。2019年至2021年，欧洲最后一道防线抗生素的消费量显着增加。

亚太地区：由于医疗保健服务的可及性提高、预期寿命延长以及孟加拉国（2024年，用于对抗被忽视的热带病）预先批准使用氨曲霉素等药物，预计亚太地区的年复合成长率将最高。

拉丁美洲、中东和非洲：由于细菌感染的流行以及与世界卫生组织倡议的合作（例如，Pfizer公司捐赠阿奇霉素用于对抗沙眼），预计成长将较为温和。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 主要国家和地区主要疾病流行情况（2025年）
  • 主要公司产品线分析
  • 关键产业趋势：併购、业务合作等
  • 主要国家和地区的监管和偿付情况

第5章 全球大环内酯类药物市场抗生素市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依产品分类
    • 阿奇霉素
    • 克拉霉素
    • 奥利霉素
    • 红霉素
    • 其他
  • 市场分析、洞察与预测：依疾病分类
    • 呼吸道感染
    • 皮肤感染
    • 性传染感染（STI）
    • 其他
  • 市场分析、洞察与预测：依给药途径分类
    • 口服
    • 肠外给药
    • 其他
  • 市场分析、洞察与预测：依年龄分类组别
    • 成人
    • 儿科
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美大环内酯类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲大环内酯类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第8章 亚太地区大环内酯类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲大环内酯类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲大环内酯类抗生素市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Crescent Pharma Ltd.
    • Wellona Pharma
    • Zydus Group
    • Merck &Co., Inc.
    • Alkem
    • Azurity Pharmaceuticals, Inc.
    • Lupin
    • Sun Pharmaceutical Industries Ltd.
Product Code: FBI113847

Growth Factors of macrolide antibiotics Market

The global macrolide antibiotics market was valued at USD 6.16 billion in 2025 and is projected to grow to USD 6.37 billion in 2026, reaching USD 8.83 billion by 2034, exhibiting a CAGR of 4.17% during the forecast period. North America dominated the market in 2025 with a 47.39% share, supported by high prevalence of bacterial infections, advanced healthcare infrastructure, and strong R&D investments. Macrolides are a class of antibiotics that inhibit bacterial protein synthesis by binding to the 50S subunit of bacterial ribosomes. These drugs, including azithromycin, clarithromycin, and erythromycin, are used to treat respiratory tract infections, skin infections, sexually transmitted diseases, and serious infections such as Campylobacter infections, particularly in children.

Key players operating in the market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Merck & Co., Inc., focusing on expanding global access, launching generics, and investing in innovative macrolide development.

Market Dynamics

Drivers: The increasing prevalence of bacterial infections worldwide is the main driver of market growth. Rising cases of respiratory infections, sexually transmitted infections (STIs), and skin infections boost demand for macrolides. For example, WHO data in July 2024 reported 82.4 million new gonorrhoeae infections among adults aged 15-49. Additionally, retail prescriptions are increasing, with approximately 105 prescriptions per 1,000 population in the U.S. in 2023, fueling macrolide usage.

Restraints: Frequent product recalls due to manufacturing defects hamper market growth by reducing consumer trust and brand reputation. For instance, in February 2025, the Health Sciences Authority of Singapore recalled clarithromycin 500 mg powder due to sterility issues, while the U.K. MHRA recalled clarithromycin tablets in December 2023 due to medical defects.

Opportunities: The rising focus on indigenous drug development in emerging markets presents substantial opportunities. Affordable local production addresses high disease burden in Asia, Africa, and Latin America. For example, India launched Nafithromycin (Miqnaf) in November 2024 targeting drug-resistant community-acquired bacterial pneumonia, supported by BIRAC.

Challenges: Adverse effects associated with macrolides, such as gastrointestinal upset, nausea, and QT interval prolongation, pose challenges to long-term adoption, particularly in erythromycin use. These effects increase the need for careful monitoring and limit usage in vulnerable populations.

Market Trends

Ongoing drug development and innovation are key trends. Research is focused on combating antibiotic resistance. For instance, in July 2024, the University of Illinois developed macrolones, dual-action antibiotics targeting both ribosomal protein synthesis and DNA replication, making bacterial resistance less likely. Such advancements are shaping future market strategies and improving the effectiveness of macrolide therapy globally.

Segmentation Analysis

By Product: Azithromycin dominates due to broad-spectrum activity, longer half-life, and fewer gastrointestinal side effects. Clarithromycin holds a substantial share, particularly in H. pylori treatment, while erythromycin benefits from generic launches and pediatric applications. Oleandomycin and other macrolides are expected to grow steadily.

By Disease Indication: Respiratory tract infections lead the market, including pneumonia, sinusitis, pharyngitis, and diphtheria. STIs are projected to grow due to rising cases of chlamydia and gonorrhea. Skin infections show moderate CAGR, fueled by acne and Staphylococcus aureus-related infections.

By Route of Administration: The oral segment dominates due to ease of use and availability, while parenteral formulations cater to hospitalized patients needing rapid action. Topical formulations are growing steadily due to site-specific applications.

By Age Group: Pediatric patients capture the dominant share, as many macrolides are approved for children. Adult usage is growing with new product launches and regulatory approvals.

By Distribution Channel: Retail pharmacies & drug stores hold the largest share, accounting for 36.1 million macrolide prescriptions in the U.S. in 2022. Online pharmacies are growing due to convenience, privacy, and cost savings. Hospital pharmacies maintain a considerable share due to first-line treatment usage in healthcare settings.

Regional Outlook

North America: Market size reached USD 2.92 billion in 2025, driven by infection prevalence, robust R&D, and funding initiatives. The U.S. leads the region due to generic launches and investments to tackle antibiotic resistance.

Europe: Holds the second-largest share, supported by increased demand for broad-spectrum antibiotics. Consumption of last-line antibiotics increased substantially between 2019-2021.

Asia Pacific: Projected to grow at the highest CAGR, fueled by better healthcare access, increasing life expectancy, and prequalification of drugs like azithromycin in Bangladesh (2024) for neglected tropical diseases.

Latin America & Middle East & Africa: Moderate growth is expected due to bacterial infections and collaborations with WHO initiatives, such as Pfizer's donation of Zithromax to control trachoma.

Competitive Landscape

The market is semi-consolidated, with key players including Pfizer Inc., Teva, Merck & Co., Lupin, Sun Pharmaceutical, Zydus Group, and others. Strategies include generic launches, collaborations, and R&D investment to maintain competitive positioning.

Conclusion

The global macrolide antibiotics market is projected to grow from USD 6.16 billion in 2025 to USD 6.37 billion in 2026, reaching USD 8.83 billion by 2034 at a CAGR of 4.17%. Growth is driven by rising bacterial infections, increasing prescriptions, and innovations addressing antimicrobial resistance. Challenges like adverse drug effects and product recalls persist, but opportunities in emerging markets and drug development strategies make the outlook favorable for both established and emerging players over the forecast period.

Segmentation By Product

  • Azithromycin
  • Clarithromycin
  • Oleandomycin
  • Erythromycin
  • Others

By Disease Indication

  • Respiratory Infections
  • Skin Infections
  • Sexually Transmitted Diseases (STIs)
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Age Group

  • Adults
  • Pediatrics

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Disease Indication, Route of Administration, Age Group, Distribution Channel, and Country/sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Diseases- by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.4. Regulatory & Reimbursement Scenarios, By Key Countries/ Regions

5. Global Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Azithromycin
    • 5.1.2. Clarithromycin
    • 5.1.3. Oleandomycin
    • 5.1.4. Erythromycin
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Respiratory Infections
    • 5.2.2. Skin Infections
    • 5.2.3. Sexually Transmitted Diseases (STIs)
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Adults
    • 5.4.2. Pediatrics
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Drug Stores & Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Azithromycin
    • 6.1.2. Clarithromycin
    • 6.1.3. Oleandomycin
    • 6.1.4. Erythromycin
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Respiratory Infections
    • 6.2.2. Skin Infections
    • 6.2.3. Sexually Transmitted Diseases (STIs)
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Adults
    • 6.4.2. Pediatrics
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Drug Stores & Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Azithromycin
    • 7.1.2. Clarithromycin
    • 7.1.3. Oleandomycin
    • 7.1.4. Erythromycin
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Respiratory Infections
    • 7.2.2. Skin Infections
    • 7.2.3. Sexually Transmitted Diseases (STIs)
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Adults
    • 7.4.2. Pediatrics
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Drug Stores & Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Azithromycin
    • 8.1.2. Clarithromycin
    • 8.1.3. Oleandomycin
    • 8.1.4. Erythromycin
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Respiratory Infections
    • 8.2.2. Skin Infections
    • 8.2.3. Sexually Transmitted Diseases (STIs)
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Adults
    • 8.4.2. Pediatrics
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Drug Stores & Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Azithromycin
    • 9.1.2. Clarithromycin
    • 9.1.3. Oleandomycin
    • 9.1.4. Erythromycin
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Respiratory Infections
    • 9.2.2. Skin Infections
    • 9.2.3. Sexually Transmitted Diseases (STIs)
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Adults
    • 9.4.2. Pediatrics
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Drug Stores & Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Macrolide Antibiotics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Azithromycin
    • 10.1.2. Clarithromycin
    • 10.1.3. Oleandomycin
    • 10.1.4. Erythromycin
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Respiratory Infections
    • 10.2.2. Skin Infections
    • 10.2.3. Sexually Transmitted Diseases (STIs)
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Adults
    • 10.4.2. Pediatrics
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Drug Stores & Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Pfizer Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Teva Pharmaceutical Industries Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Crescent Pharma Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Wellona Pharma
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Zydus Group
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Merck & Co., Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Alkem
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Azurity Pharmaceuticals, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Lupin
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Sun Pharmaceutical Industries Ltd.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 3: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 5: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: Global Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 8: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 9: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table10: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 11: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 14: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 15: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 16: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 17: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 20: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 21: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 22: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 23: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 26: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 27: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 29: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 32: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
  • Table 33: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 34: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 35: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Macrolide Antibiotics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Macrolide Antibiotics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Macrolide Antibiotics Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Macrolide Antibiotics Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 6: Global Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Macrolide Antibiotics Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 10: North America Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 11: North America Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 12: North America Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 13: North America Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 14: North America Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 15: North America Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 16: North America Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Macrolide Antibiotics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Macrolide Antibiotics Market Value Share (%), By Country, 2025
  • Figure 20: Europe Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 21: Europe Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 22: Europe Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 23: Europe Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 24: Europe Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Europe Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 26: Europe Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 27: Europe Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 28: Europe Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 34: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 35: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 36: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 37: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 38: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 39: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 40: Asia Pacific Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 45: Latin America Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 46: Latin America Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 47: Latin America Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 48: Latin America Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 49: Latin America Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 50: Latin America Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 51: Latin America Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 52: Latin America Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 57: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Product, 2025
  • Figure 58: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 59: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Disease Indication, 2025
  • Figure 60: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 61: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Route of Administration, 2025

2025 & 2034

  • Figure 62: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 63: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Age Group, 2025
  • Figure 64: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Macrolide Antibiotics Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Macrolide Antibiotics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Macrolide Antibiotics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Macrolide Antibiotics Market Share (%), By Company, 2025